Published on

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide


  1. 1. Disorders of Sexual Differentiation Pediatric GU Review UCSD Pediatric Urology George Chiang MD Sara Marietti MD Outlined from The Kelalis-King-Belman Textbook of Clinical Pediatric Urology 2007 (not for reproduction, distribution, or sale without consent)
  2. 3. Outline <ul><li>Embryology </li></ul><ul><li>Classification </li></ul><ul><li>Disorders </li></ul><ul><li>Workup </li></ul><ul><li>Cases </li></ul><ul><li>SESAP Questions </li></ul>
  3. 4. Chromosomal sex Gonadal sex Phenotypic sex Sexual Differentiation
  4. 5. Chromosomal Sex <ul><li>Genes associated with sex determination </li></ul><ul><ul><li>TDF (testis-determining factor) = SRY (sex-determining region Y gene) </li></ul></ul><ul><ul><li>WT-1 = commitment and maintenance of gonadal tissue </li></ul></ul><ul><ul><li>SF-1 = regulator of mullerian inhibiting substance </li></ul></ul><ul><ul><li>SOX-9 </li></ul></ul><ul><ul><li>DAX-1 (X linked) </li></ul></ul>
  5. 6. “ Development” TDF SRY Testis Testosterone Müllerian Inhibiting Substance Penis Vas Deferns Prostate Uterus Fallopian Tubes Upper Vagina
  6. 7. Testicle Differentiation <ul><li>Testicle- Sertoli and Leydig cells </li></ul><ul><ul><li>Leydig cells - testosterone </li></ul></ul><ul><ul><ul><li>8-12 weeks </li></ul></ul></ul><ul><ul><ul><li>Virilization external genitalia </li></ul></ul></ul><ul><ul><ul><li>Wolfian ducts  Vas deferens </li></ul></ul></ul><ul><ul><li>Sertoli cells- MIS </li></ul></ul><ul><ul><ul><li>Müllerian Inhibiting Substance </li></ul></ul></ul><ul><ul><ul><li>8-10 weeks </li></ul></ul></ul><ul><ul><ul><li>Regression of Müllerian structures </li></ul></ul></ul>
  7. 8. Ovarian Differentiation <ul><li>Absence of SRY </li></ul><ul><li>No testosterone or MIS </li></ul><ul><li>Maintenance of Müllerian structures </li></ul><ul><ul><li>Fallopian tubes </li></ul></ul><ul><ul><li>Uterus </li></ul></ul><ul><ul><li>Upper 2/3 vagina </li></ul></ul><ul><li>“ Feminization” of external genitalia </li></ul>
  8. 9. Board Questions: <ul><li>Paramesonephric (Mullerian) duct </li></ul><ul><li>Mesonephric (Wolffian) duct </li></ul>Gartner’s Duct Prostatic Utricle Appendix Testes Appendix Epididymis Epoophoron
  9. 13. Male Phenotypic Sexual Differentiation <ul><li>Masculinization of the male fetus starts between 7-8 weeks gestation and is complete by 12-13 weeks </li></ul><ul><li>MIS in males acts locally and unilaterally to suppress mullerian ducts </li></ul><ul><ul><li>(Fallopian tubes, Uterus, Upper 2/3 of the Vagina) </li></ul></ul><ul><li>Testosterone in males permits local development of the wolffian ducts </li></ul><ul><ul><li>(Epididymis, Vas deferens, Seminal vesicles, Prostate) </li></ul></ul>
  10. 14. Female Phenotypic Sexual Differentiation <ul><li>The absence of circulating testosterone in the female fetus maintains the appearance of the external genitalia at the 6-week gestational stage </li></ul>
  11. 16. Tanner Stages
  12. 17. Classification <ul><li>Intersex (or DSD) vs. Ambiguous genitalia </li></ul><ul><li>Workup and classification are not straightforward </li></ul><ul><li>Only testicular tissue descends </li></ul><ul><li>Gonad causes ipsilateral mullerian duct development/regression </li></ul>
  13. 18. Hughes IA, Houk C, Ahmed SF, Lee PA. Consensus statement on the management of intersex disorders. Archives of Disease in Childhood 2006 <ul><li>Consensus panel, organized by the Lawson Wilkins Pediatric Endocrine Society (LWPES) and the European Society for Pediatric Endocrinology (ESPE): </li></ul><ul><li>advocated that the term “Disorders of Sexual Development” (DSD), now be used for congenital conditions with discordance of genotypic, gonadal, and/or phenotypic sex </li></ul>
  14. 19. HWA Protests Intersex Genital Mutilation [Washington, DC: 21 Apr 98] A dozen members of Hermaphrodites With Attitude and Transexual Menace picketed outside the George Washington University Hospital, protesting GWU's cutting of intersexed infants' genitals to make them resemble 'normal' male and female genitals . Hermactivists call this medical intervention Intersex Genital Mutilation (IGM). &quot; Not only are American doctors cutting into 7 intersexed infants every working day, but people like GWU's Dr. Barry Belman are telling parents they have to do it for the good of the infant ,&quot; said Cheryl Chase, founder of HWA. &quot;Mutilating my genitals wasn't for my good; it was to make the doctors and my parents more comfortable with my body.&quot; After the demo, several protestors visited GWU Hospital departments that take part in IGM--OB/GYN, Endocrinology, Pediatrics and Plastic Surgery--to discuss their concerns with caregivers and, as one hermactivist put it, to speak for the infants who cannot speak for themselves. From In Your Face on-line news, April 1998
  15. 20. First and foremost, we recommend avoidance of harmful or unnecessary genital surgery on infants and children. No surgery should be performed unless it is absolutely necessary for the physical health and comfort of the intersexual child . We believe any surgery that does not meet these criteria to be essentially elective cosmetic surgery which should be deferred until the intersexual child is able to understand the risks and benefits of the proposed surgery and is able to provide appropriately informed consent.
  16. 21. Disorders of Sex Development <ul><li>Female Pseudohermaphrodite </li></ul><ul><ul><li>46 XY DSD </li></ul></ul><ul><li>XX Male or XX sex reversal </li></ul><ul><ul><li>46 XX testicular DSD </li></ul></ul><ul><li>XY sex reversal </li></ul><ul><ul><li>46, XY complete gonadal dysgenesis </li></ul></ul><ul><li>True hermaphrodite </li></ul><ul><ul><li>Ovotesticular DSD </li></ul></ul><ul><li>Male pseudohermaphrodite </li></ul><ul><ul><li>46 XY DSD </li></ul></ul>
  17. 22. Intersex <ul><li>Disorders of gonadal differentiation </li></ul><ul><li>True Hermaphrodite </li></ul><ul><li>Female Pseudohermaphrodite </li></ul><ul><ul><li>Masculinized female </li></ul></ul><ul><ul><li>Ovaries present but external genitalia virilized </li></ul></ul><ul><li>Male Pseudohermaphrodite </li></ul><ul><ul><li>Testes present but genital ducts or external genitalia not completely virilized </li></ul></ul>
  18. 23. Wide range of phenotypes
  19. 24. Disorders of Gonadal Differentiation <ul><li>Klinefelter </li></ul><ul><li>Turner’s Syndrome </li></ul><ul><li>Mixed gonadal dysgenesis </li></ul><ul><li>Pure gonadal dysgenesis </li></ul><ul><li>Bilateral vanishing testis/testicular regression </li></ul>
  20. 25. Klinefelter’s <ul><li>1 in 1000 males </li></ul><ul><li>Gynecomastia, increased GnRH, small testes </li></ul><ul><li>47 XXY </li></ul><ul><li>Azospermia with low normal Testosterone </li></ul><ul><li>Not ambiguous </li></ul>
  21. 26. Turner’s Syndrome <ul><ul><li>45,X female phenotype </li></ul></ul><ul><ul><li>One normal functioning X chromosome, can have mosaicism; </li></ul></ul><ul><ul><li>Presence of Y increases masculinization and gonadoblastoma </li></ul></ul><ul><ul><li>1/2500 live births </li></ul></ul><ul><ul><li>No secondary sexual characteristics </li></ul></ul><ul><ul><li>Multiple cardiac and renal anomalies </li></ul></ul><ul><ul><li>Search for Y chromosome and prophylactic gonadectomy if Y found </li></ul></ul><ul><ul><li>Streak gonad (oocytes undergo rapid apoptosis in fetal period- 2-3 cm in broad ligament) </li></ul></ul><ul><ul><li>FSH/LH elevated </li></ul></ul><ul><ul><li>Ultrasound for renal and cardiac anomalies </li></ul></ul><ul><ul><li>Growth hormone to improve stature and exogenous estrogen at 12-15 years to induce puberty </li></ul></ul><ul><ul><li>Not ambiguous </li></ul></ul>
  22. 27. <ul><li>2nd most common DSD </li></ul><ul><li>XO/XY Mosaic Karyotype (45X0/46XY) </li></ul><ul><li>Testis and a Streak </li></ul><ul><li>Wolffian structures with testis </li></ul><ul><li>Mullerian structures with streak </li></ul>Mixed Gonadal Dysgenesis
  23. 28. <ul><li>Hypospadias plus </li></ul><ul><li>Unilateral undescended testis </li></ul><ul><li>“ Bilateral” undescended testis </li></ul><ul><li>(If neither testis is palpable, could be female CAH) </li></ul><ul><li>-Can be ambiguous genitalia or normal male genitalia </li></ul>Mixed Gonadal Dysgenesis
  24. 29. <ul><li>Treat according to genital potential ??? </li></ul><ul><ul><li>2/3 raised as female </li></ul></ul><ul><li>Higher risk of Wilms’ tumor </li></ul><ul><li>What about the testis if raised male ? </li></ul><ul><ul><li>- Bring it down or Remove it </li></ul></ul><ul><ul><li>- Annual testis ultrasounds after puberty </li></ul></ul>Mixed Gonadal Dysgenesis
  25. 30. Pure Gonadal Dysgenesis <ul><li>46 XY [46XX is straightforward] </li></ul><ul><li>Abnormality of SRY gene that eliminates SRY function </li></ul><ul><li>Bilateral streak gonad with similar Turner’s histology </li></ul><ul><li>30% risk of gonadoblastoma by 30 </li></ul><ul><li>Normal female genitalia , well developed Mullerian structures </li></ul><ul><li>Delayed puberty, elevated FSH/LH, amenorrhea </li></ul><ul><li>Treat with removal of streak gonads, cyclic hormonal replacement </li></ul><ul><li>Not Ambiguous </li></ul>
  26. 31. Embryonic Testicular Regression and Bilateral Vanishing Testes <ul><li>Genetic mutation vs teratogen vs bilateral torsion </li></ul><ul><li>3 phenotypes </li></ul><ul><ul><ul><li>Early before 60-70 days gestation with female phenotype and no inner ductal or Wolfian structures </li></ul></ul></ul><ul><ul><ul><li>Intermediate: ambiguous genitalia, absent gonads, no internal Mullerian structures, some elongation of phallus </li></ul></ul></ul><ul><ul><ul><li>Late: microphallus, absent testes, fully developed Wolfian structues (bilateral vanishing testes) </li></ul></ul></ul><ul><li>Diagnosis: Elevated FSH/LH and castrate testosterone levels; 46 XY </li></ul><ul><li>Management </li></ul><ul><ul><li>Phenotypic females  estrogen supplementation and dilation of vagina vs. reconstruction </li></ul></ul><ul><ul><li>Phenotypic Males  Androgen replacement can succesfully result in normal penis, secondary sexual characteristics </li></ul></ul>
  27. 32. True Hermaphrodite <ul><li>Ambiguous genitalia </li></ul><ul><li>1 ovary or 1 testes or ovotestis </li></ul><ul><ul><li>Ovary usually on left and testis or ovotestis on right </li></ul></ul><ul><li>Hidden mosaicism with a Y cell ine </li></ul><ul><li>60% 46 XX, 33% mosaicism </li></ul><ul><li>75% raised as males </li></ul><ul><li>Gender assignment based on functional potential </li></ul><ul><li>Potential for fertility as female unlike males </li></ul><ul><li>Monitor for tumors </li></ul>
  28. 33. Female Pseudohermaphrodite <ul><li>Etiologies include CAH and maternal virilizing hormone </li></ul><ul><ul><li>Defect in one of 5 enzymes </li></ul></ul><ul><ul><ul><li>21 hydroxylase (95%) </li></ul></ul></ul><ul><ul><ul><ul><li>CYP21 gene on 6p21.3 </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Autosomal recessive </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Salt-wasters (75%)  shock within 1-2 weeks after birth, simple virilizers (25%)  males Diagnosis with elevated plasma levels of progesterone and 17 OH progesterone (pelvic u/s demonstrates mullerian tissues; adrenal u/s demonstrates enlargement) </li></ul></ul></ul></ul><ul><ul><ul><li>11B-hydroxylase (5%) </li></ul></ul></ul><ul><ul><ul><ul><li>HTN common from increased levels of deoxycorticosterone </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Increased plasma 11-DOC and 11-deoxycortisol; urinary levels of 17-ketosteroids and 17-hydroxysteroids increased </li></ul></ul></ul></ul><ul><ul><ul><li>3 B-hydroxysteroid dehydrogenase </li></ul></ul></ul><ul><ul><ul><ul><li>Impaired synthesis of aldosterone, cortisol, and sex steroids </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Elevated serum 17-hydroxpregnenalone and DHEA </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Autosomal recessive </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Females have clitoral enlargement and labial fusion (mullerian structures by pelvic u/s) </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Males have hypospadias and masculinize later </li></ul></ul></ul></ul>
  29. 34. Female Pseudohermaphrodite <ul><li>Maternal androgen exposure: </li></ul><ul><ul><li><12 weeks Progestational agents or maternal tumor (luteoma, arrhenoblastoma, adrenal CA ) </li></ul></ul><ul><ul><li>Medications:2% of female infants if tx with progestins in-utero ( Danazol) </li></ul></ul><ul><li>Prenatal treatment </li></ul><ul><ul><li>Dexamethasone at 5-6 weeks GA </li></ul></ul><ul><ul><li>Can assay for 17-OH progesterone at 16-17 weeks </li></ul></ul><ul><ul><li>3 of 4 children do not need the treatment </li></ul></ul><ul><li>Postnatal treatment </li></ul><ul><ul><li>Supply deficient hormone to suppress ACTH </li></ul></ul><ul><ul><li>Mineralocorticoid replacement for salt wasters </li></ul></ul><ul><ul><li>Feminizing genitoplasty at 3-6 months </li></ul></ul><ul><ul><li>Prophylactic adrenalectomy for salt losers and severely masculinized females </li></ul></ul>
  30. 35. 21-Hydroxylase deficiency Testosterone
  31. 36. FEMALE CAH
  32. 37. Female CAH
  33. 38. Female CAH
  34. 40. <ul><li>Inadequate production of testosterone </li></ul><ul><li>Inadequate metabolism of testosterone </li></ul><ul><li>End-organ sensitivity to testosterone </li></ul><ul><li>Inadequate production of MIS </li></ul>Male Pseudohermaphrodite
  35. 41. Male Pseudohermaphrodite <ul><li>Inadequate production </li></ul><ul><ul><li>Defect in 5 enzymes can cause incomplete or absent virlization </li></ul></ul><ul><ul><li>StAR, 3 B-hydroxysteroid, 17alpha-hydroxylase, 17,20 lyase, 17 B-hydroxysteroid oxidoreductase </li></ul></ul>
  36. 42. Male Pseudohermaphrodite <ul><li>Inadequate metabolism </li></ul><ul><ul><li>5 alpha reductase deficiency </li></ul></ul><ul><ul><li>46 XY karyotype varying from penoscrotal hypospadias to markedly ambiguous genitalia </li></ul></ul><ul><ul><li>Partial masculinization at puberty “guevedoces” </li></ul></ul><ul><ul><li>Elevated mean plasma testosterone/DHT ratios </li></ul></ul><ul><ul><ul><li>hCG stim can increase from 3-25 to 75-160 </li></ul></ul></ul><ul><ul><li>Diagnose with genital skin fibroblasts cultures </li></ul></ul><ul><ul><li>Tx: male sex rearing; if female, early gonadectomy </li></ul></ul>
  37. 43. Male Pseudohermaphrodite <ul><li>End organ sensitivity </li></ul><ul><li>CAIS </li></ul><ul><ul><li>Phenotypic unambiguous female </li></ul></ul><ul><ul><li>Evaluation of inguinal hernia (50%) with testis or primary amenorrhea, lack of pubic/axillary hair </li></ul></ul><ul><ul><li>Absence of Mullerian derivatives </li></ul></ul><ul><ul><li>Fetal testes secrete MIS and have absent spermatogenesis with normal or hyperplastic Leydig cells </li></ul></ul><ul><ul><li>At puberty gonadotropin levels rise with increased estradiol and breast development </li></ul></ul><ul><ul><li>Timing of gonadectomy controversial (if early, no estradiol; if late, risk of malignancy) </li></ul></ul>
  38. 44. Male Pseudohermaphrodite <ul><li>PAIS </li></ul><ul><ul><li>Variable ambiguity </li></ul></ul><ul><ul><li>Repair of hypospadias and/or cryptorchidism </li></ul></ul><ul><ul><li>Diagnosis </li></ul></ul><ul><ul><ul><li>46 XY ambiguous genitalia and absent Mullerian structures on pelvic u/s </li></ul></ul></ul><ul><ul><li>Management depends on degree of ambiguity </li></ul></ul>
  39. 45. Male Pseudohermaphrodite <ul><li>Inadequate production of MIS </li></ul><ul><li>Persistent Mullerian Duct </li></ul><ul><ul><li>46 XY </li></ul></ul><ul><ul><li>Normal male external genitalia with internal mullerian duct structures </li></ul></ul><ul><ul><li>Unilateral or bilateral undescended testes, fallopian tubes, uterus, and upper vagina draining a prostatic utricle </li></ul></ul><ul><ul><li>PMDS defect in MIS on Chromosome 19p13 or receptor on chromosome 12q13 </li></ul></ul><ul><ul><li>Tx with orchiopexy; risk of malignancy in retained mullerian structures </li></ul></ul>
  40. 46. <ul><li>Classic ambiguous genitalia </li></ul><ul><li>Female with palpable gonads </li></ul><ul><li>Male with nonpalpable gonads </li></ul><ul><li>Hypospadias and cryptorchidism </li></ul><ul><li>“ Normal” Female or Male </li></ul>Common Nenonatal Presentations
  41. 49. <ul><li>History </li></ul><ul><ul><li>Born to a 32 yo G5P4 female at ~34 weeks gestation </li></ul></ul><ul><ul><li>Prenatal care begun at ~1 month </li></ul></ul><ul><ul><li>Triple screen showed low estriol </li></ul></ul><ul><ul><li>Amniocentesis negative </li></ul></ul><ul><ul><li>No family history of intersex disorders </li></ul></ul><ul><ul><li>No known prenatal exposures </li></ul></ul>Case #1
  42. 50. Case #1
  43. 51. Physical Exam <ul><li>Physical Exam </li></ul><ul><ul><li>General exam WNL </li></ul></ul><ul><ul><li>Genitalia </li></ul></ul><ul><ul><ul><li>Fused labia majora with slight hyperpigmentation </li></ul></ul></ul><ul><ul><ul><li>Single perineal opening </li></ul></ul></ul><ul><ul><ul><li>Slightly enlarged clitoris </li></ul></ul></ul><ul><ul><ul><li>No palpable gonads </li></ul></ul></ul>
  44. 52. Workup? <ul><li>Labs </li></ul><ul><ul><li>Electrolytes all WNL x 12 days in NICU </li></ul></ul><ul><ul><li>Karyotype – 46, XX </li></ul></ul><ul><ul><li>Androstenediol – WNL </li></ul></ul><ul><ul><li>Deoxycortisone – elevated </li></ul></ul><ul><ul><li>DHEA – elevated </li></ul></ul><ul><ul><li>Testosterone – insufficient initially, sl elevated at 1 month </li></ul></ul><ul><ul><li>17-Hydroxyprogesterone - elevated </li></ul></ul>
  45. 53. Workup?
  46. 54. Plan? <ul><li>Multidisciplinary approach </li></ul><ul><li>Stabilize electrolytes if necessary </li></ul><ul><li>Plan for surgical management </li></ul>
  47. 55. Voiding Cystourethrogram
  48. 56. Case #2 <ul><li>6 month old presents with undescended testicle </li></ul><ul><li>Past Sur Hx: None </li></ul><ul><li>Past Med Hx: No prenatal care </li></ul><ul><li>Meds: None </li></ul>
  49. 59. Workup/Plan? <ul><li>Karyotype 45X/46XY </li></ul>
  50. 60. Case 3 <ul><li>12 year old female presents with bilateral inguinal hernias </li></ul>
  51. 61. Case 3
  52. 62. QUESTIONS
  53. 63. <ul><li>The earliest clinically detectable pubertal change in a boy is: </li></ul><ul><li>Enlargement of the testes </li></ul><ul><li>Appearance of pubic hair </li></ul><ul><li>Deepening of the voice </li></ul><ul><li>Scrotal rugation </li></ul><ul><li>Increase in phallic length </li></ul>
  54. 64. <ul><li>Inhibin is a substance derived from the testicle which mediates secretion of: </li></ul><ul><li>Testosterone </li></ul><ul><li>FSH </li></ul><ul><li>LH </li></ul><ul><li>GnRH </li></ul><ul><li>Mullllerian inhibiting factor </li></ul>
  55. 65. <ul><li>During the first three years of life, hymenal morphology demonstrates progression of its: </li></ul><ul><li>Redundancy </li></ul><ul><li>External ridging </li></ul><ul><li>Notching </li></ul><ul><li>Annular configuration </li></ul><ul><li>Crescentic configuration </li></ul>
  56. 66. <ul><li>The diagnosis of testicular agenesis is confirmed by: </li></ul><ul><li>Absence of an ipsilateral kidney </li></ul><ul><li>Absence of an ipsilateral vas deferens </li></ul><ul><li>Blind-ending testicular vessels </li></ul><ul><li>Ipsilateral scrotal hypoplasia </li></ul><ul><li>Ipsilateral mullerian structures </li></ul>
  57. 67. <ul><li>5-alpha-reductase deficiency is associated with: </li></ul><ul><li>Poorly differentiated Wolffian structures </li></ul><ul><li>Poorly differentiated Mullerian structures </li></ul><ul><li>Gynecomastia </li></ul><ul><li>Elevated concentration of testosterone at puberty </li></ul><ul><li>Elevated dihydrotestosterone-testosterone ratio </li></ul>
  58. 68. <ul><li>Unilateral renal agenesis is associated with an increased incidence of: </li></ul><ul><li>Ipsilateral anorchia </li></ul><ul><li>2 vessel umbilical cord </li></ul><ul><li>Ipsilateral adrenal agenesis </li></ul><ul><li>Mullerian duct abnormalities </li></ul><ul><li>Urethral anomalies </li></ul>
  59. 69. <ul><li>A 3 year old phenotypic girl undergoes an abdominal and pelvic ultrasound for intermittent abdominal pain. No uterus is seen on the ultrasounds. Right and left gonads are identified in their respective inguinal canals. Karyotype is 46 XY. The next step is: </li></ul><ul><li>Genetic sequencing of the patient’s androgen receptor gene </li></ul><ul><li>Serum for LH, FSH and serum testosterone </li></ul><ul><li>Serum for mullerian inhibitory factor </li></ul><ul><li>Serum for 17-OH </li></ul><ul><li>Gonadal biopsy </li></ul>
  60. 70. <ul><li>A 22 year old man with CAH has bilateral testicular masses. The next step is: </li></ul><ul><li>Serum ACTH and cortisol </li></ul><ul><li>Serum LH and testosterone </li></ul><ul><li>Pituitary MRI scan </li></ul><ul><li>Percutaneous testis biopsy </li></ul><ul><li>Bilateral excisional biopsies </li></ul>
  61. 71. <ul><li>A 3 year old girl has normal external genitalia and an absent vagina. Her chromosomes are 46 XY. The most common associated finding is: </li></ul><ul><li>Unilateral gonadal agenesis </li></ul><ul><li>Tethered spinal cord </li></ul><ul><li>Unilateral renal agenesis </li></ul><ul><li>Inguinal hernia </li></ul><ul><li>VUR </li></ul>
  62. 72. <ul><li>A 38 year old woman undergoes amniocentesis at 24 weeks gestation. The fetal karytotype is 45X/46XY. The gonads will most likely be: </li></ul><ul><li>Bilateral streak gonads </li></ul><ul><li>Streak gonad and testis </li></ul><ul><li>Streak gonad and ovary </li></ul><ul><li>Streak gonad and dysgenetic testis </li></ul><ul><li>Bilateral testes </li></ul>
  63. 73. <ul><li>A phenotypically normal 3 year old girl has bilateral inguinal hernias. During a hernia repair, the gonad is discovered within the hernia sac. Frozen section biopsy documents that it is a testis. These findings suggest: </li></ul><ul><li>Persistent mullerian duct syndrome </li></ul><ul><li>True hermaphroditism </li></ul><ul><li>Complete androgen insensitivity </li></ul><ul><li>Mixed gonadal dysgenesis </li></ul><ul><li>Adrenogenital syndrome </li></ul>
  64. 74. <ul><li>A 17 year old-boy undergoes evaluation for delayed puberty. He is above average height, has bilateral small testes, and gynecomastia. Serum FSH and LH are elevated and testosterone is low. The patient is at increased risk for: </li></ul><ul><li>Breast cancer </li></ul><ul><li>Gonadoblastoma </li></ul><ul><li>Testicular cancer </li></ul><ul><li>Prostate cancer </li></ul><ul><li>TCC </li></ul>